Table 3.
The Pharmacokinetic Parameters and the Relative Bioavailability Percentages of Agomelatine Following the Transdermal Application of Agomelatine-Loaded I2-LFU-C4 System and the Oral Administration of Agomelatine Aqueous Dispersion in Rabbits (Mean ± S.D., n = 6)
| Treatments | Oral Agomelatine Aqueous Dispersion | Transdermal I2-LFU-C4 System |
|---|---|---|
| Cmax (ng/mL) | 27.94 ± 5.50 | 178.93 ± 20.20 |
| *Tmax (h) | 0.5 (0.5–0.5) | 0.5 (0.5–1) |
| *MRT0-∞ (h) | 3.09 (2.37–3.54) | 2.73 (2.36–3.14) |
| Tel (h) | 2.40 ± 0.26 | 2.57 ± 0.20 |
| AUC0-12h (ng.h/mL) | 48.85 ± 7.09 | 354.47 ± 44.73 |
| AUC0-∞ (ng.h/mL) | 49.94 ± 7.40 | 364.42 ± 46.87 |
| % relative bioavailability based on AUC(0–12) | 725.6 | |
| % relative bioavailability based on AUC(0–∞) | 729.7 | |
Note: *Median (range).
Abbreviations: Cmax, peak plasma concentration; Tmax, time to reach Cmax; MRT, mean residence time; Tel, elimination half-life; AUC(0–12h), area under the curve from zero to the last sampling point; AUC(0–∞), area under the curve from zero to infinity.